Trader consensus prices "No" at 83.5% for a new WHO-designated COVID-19 variant of concern before 2027, driven by the absence of any such classification since Omicron in late 2021, amid SARS-CoV-2's evolution into milder Omicron sublineages bolstered by widespread population immunity and updated vaccines. Recent emergence of the highly mutated BA.3.2 ("Cicada") variant—first noted in late 2024 and now circulating in 25+ countries including the US—has prompted close surveillance as a variant under monitoring due to potential immune escape from 70+ spike mutations, but lacks evidence of increased transmissibility, severity, or hospitalizations to warrant VOC status per WHO and ECDC criteria as of late March 2026. WHO's May antigen deliberations could signal shifts, though current trends favor containment without escalation.